Matthew J. Frank

Palo Alto University — United States

Medicine · Health Sciences

26h-index3.5kcitations213works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(128), Lymphoma Diagnosis and Treatment(42), Biosimilars and Bioanalytical Methods(23), Immune Cell Function and Interaction(20), Biomedical Ethics and Regulation(18)

Publications213 total

Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas
Leukemia & lymphoma/Leukemia and lymphoma·2025
Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Blood Cancer Discovery·2025Open Access
Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)
Blood·2025Open Access
Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)
Blood·2025
Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation
Blood·2025Open Access
Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL
Blood·2025Open Access
Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel
Blood·2025
Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results
Blood·2025Open Access
Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy
Blood·2025
Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT
Blood·2025Open Access
Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)
Blood·2025Open Access
Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy
Blood·2025Open Access
Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma
Blood·2025Open Access
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias
2025Open Access
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Cytotherapy·2025Open Access
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>
Transplantation and Cellular Therapy·2025Open Access
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Blood Advances·2025· 1 citedOpen Access
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Blood Advances·2025· 7 citedOpen Access
427 | MONITORING CIRUCLATING TUMOR DNA IMPROVES EARLY RELAPSE DETECTION AFTER STANDARD OF CARE 2L+ AXI‐CEL IN LBCL: A PROSPECTIVE STUDY
Hematological Oncology·2025Open Access
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
Blood Advances·2025· 2 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

David B. Miklos(38), Lori Muffly(24), Robert S. Negrin(21), Sally Arai(20), Everett Meyer(20), Andrew R. Rezvani(20), Parveen Shiraz(19), Robert Lowsky(19), Surbhi Sidana(19), Laura Johnston(17), Wen‐Kai Weng(17), Jay Y. Spiegel(15), Bita Sahaf(15), Judith A. Shizuru(15), Juliana Craig(12), John Tamaresis(11), Crystal L. Mackall(11), Saurabh Dahiya(11), John H. Baird(8), Yasodha Natkunam(8)